ArticleMolecular cancer therapeutics2025

Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody-Drug Conjugate.

Chi-Sheng Shia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.